drugset / Trial / NCT01326468
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with advanced head and neck cancer is at high risk of recurrence at the primary site or in the neck. Part of normal treatment is to treat such patients with chemotherapy and radiation. The chemotherapy can include Erbitux. The purpose of this study is to treat such patients with an additional agent, Torisel. This study tests the doses of Torisel that can be safely administered together with radiation and chemotherapy.
Timeline
- Start
- 2011-12-08
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 30 mg/m2 | — |
| Subject | Temsirolimus | Small molecule | 15 mg | Intravenous |
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |
| Background | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |